Now Playing
Opinion|Videos|February 8, 2024
CONTACT-02: Cabozantinib Plus Atezolizumab in mCRPC
Following ASCO GU 2024, Tian Zhang, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from CONTACT-02 investigating cabozantinib plus atezolizumab in metastatic castration-resistant prostate cancer.
Advertisement
Advertisement
Related to this article
Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.
Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Updated survival findings, perioperative treatment strategies, and circulating tumor DNA analyses highlight evolving approaches to genitourinary cancers.
The approval expands the combination’s use to patients with androgen pathway modulation–naive or –sensitive disease based on phase 3 TALAPRO-3 findings.
Advertisement
Advertisement
Trending on Targeted Onc
1
A New Era in Sarcoma Treatment? Dr Banks on the Potential of TIL Therapy
2
FDA Finalizes Potency Guidance for Cell and Gene Therapy Products
3
FDA Approves Generic Venetoclax Tablets for CLL/SLL and AML
4
Enzalutamide Fails to Improve Survival in High-Risk Prostate Cancer
5